| License: Creative Commons Attribution 4.0 PDF - Published Version (1MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-524407
- DOI to cite this document:
- 10.5283/epub.52440
Bumes, Elisabeth 
; Fellner, Claudia ; Fellner, Franz A. ; Fleischanderl, Karin ; Häckl, Martina ; Lenz, Stefan ; Linker, Ralf A. ; Mirus, Tim ; Oefner, Peter J. ; Paar, Christian ; Proescholdt, Martin A. ; Riemenschneider, Markus J. ; Rosengarth, Katharina ; Weis, Serge ; Wendl, Christina ; Wimmer, Sibylle ; Hau, Peter ; Gronwald, Wolfram ; Hutterer, Markus
; Fellner, Claudia ; Fellner, Franz A. ; Fleischanderl, Karin ; Häckl, Martina ; Lenz, Stefan ; Linker, Ralf A. ; Mirus, Tim ; Oefner, Peter J. ; Paar, Christian ; Proescholdt, Martin A. ; Riemenschneider, Markus J. ; Rosengarth, Katharina ; Weis, Serge ; Wendl, Christina ; Wimmer, Sibylle ; Hau, Peter ; Gronwald, Wolfram ; Hutterer, Markus Abstract
The isocitrate dehydrogenase (IDH) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of ...
Owner only: item control page
Download Statistics